Board of Directors

Peter Samuel Wulff (Chairman of the Board)

Peter Wulff is the President & CEO of Sentinext Therapeutics Sdn Bhd, a Malaysian vaccine company. Peter Wulff received his master degree in Organic Chemistry from the University of Copenhagen 1980 and became European Patent Attorney in 1992. Peter was Co-founder and President & CEO, Bavarian Nordic A/S from 1994 to 2007, Co-founder and  Director of Patents and Licensing and Corporate Management member, NeuroSearch A/S from 1989 to 1997 and Director of Patents and Licensing, A/S Ferrosan from 1987 to 1989. Peter is Board member of Dansk Biotek from May 2008.

Leif Helth Jensen

Investment Manager at CAT Science Park. Leif Helth Jensen has more than 25 years of experience within the life science industry. He has been the CEO of two Biotech companies (Cureon and Glycom), on the Board of Directors in 7 Biotech companies (Genmab, Zealand Pharma, Cureon, Exiqon, Meditel, Dentofit and Promogenetics) and been the co-founder of 4 Biotech companies (NeuroSearch, Zealand Pharma, Synome (UK) and Cureon). He is currently Chairman of Valderm, Microlytic, Global Aviation and Bone Medical (Australia) and member of the Board in Alcorlab and Serendex.He has previously held other positions such as Director of Pharmacology at NeuroSearch, CEO of Danske Life Science and VicePresident Portfolio Management at LifeCycle Pharma.

Stephan Christgau

Stephan Christgau is Investment Director at Novo Seeds. He holds a PhD in diabetes immunology from DTU and UCSF. Stephan has served as Executive Vice President; COO of Osteologix, Senior research scientist at Nordic Bioscience (2001 – 2003) and Osteometer Biotech (1995-2001) and research scientist and project leader at Novo Nordisk. He is currently on the board of EpiTherapeutics and previously served on the board of Osteologix Aps. Stephan Christgau is the author on more than 60 scientific publications and inventor on more than 25 patent families.

Christian E. Elling

Dr Elling is a co-founder of 7TM Pharma and serves as Vice President, responsible for Biology and Development, including pre-clinical development, clinical development and CMC/pharmaceutical sciences. Dr Elling received his early training in Biochemistry, and received his Ph.D. from University of Copenhagen, Denmark. His early research interests included the molecular mechanism of action of 7TM receptors, particularly how receptors may be turned on or off at the molecular level. His current research and therapeutic interests include obesity and related co-morbidities. He serves on the steering committee for Biologue-Danish Pharma Consortium for The Danish Association of Biotechnology Industries.

Thomas N.Kledal (CEO)

Dr. Kledal is the founder and CEO of INAGEN.  He possesses a PhD in molecular pharmacology from the University of Copenhagen and is the author of numerous papers in the field of molecular pharmacology and virology.  Thomas Kledal comes from a position as Senior Scientist at the Danish Technical University.